Shield Therapeutics - £1.5 million placing supporting growth of ACCRUFeR

Shield Therapeutics plc has successfully completed a placing, raising £1.5 million to support the growth of ACCRUFeR®. The placing was well received by institutional investors and the issue price represents a 5% premium to the existing shares. Post-admission, the company will have 1,061,690,484 ordinary shares in issue. This move strengthens the company's working capital position and allows management to focus on accelerating sales of ACCRUFeR®. CFO Santosh Shanbhag expressed confidence in turning cash flow positive by the end of 2025. For more information, please contact Shield Therapeutics plc or visit their website. Investors are welcome to ask questions about this placing and the company's future plans.